Logo for Relmada Therapeutics Inc

Relmada Therapeutics Investor Relations Material

Latest events

Logo for Relmada Therapeutics Inc

Status Update

Relmada Therapeutics
Logo for Relmada Therapeutics

Status Update

28 Apr, 2025
Logo for Relmada Therapeutics

Q4 2024

27 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies

Latest reports from Relmada Therapeutics Inc

Access all reports
Relmada Therapeutics Inc. is a clinical-stage biotechnology company focusing on developing innovative treatments for central nervous system (CNS) diseases, with a particular emphasis on major depressive disorder. The company's flagship product, esmethadone (d-methadone, dextromethadone, REL-1017), is a novel N-methyl-D-aspartate (NMDA) receptor antagonist currently inclinical trials, aimed at serving as an adjunctive or monotherapy treatment for MDD in adults. The company is headquartered Coral Gables, Florida. Its shares are listed on the Nasdaq.